Efficacy and Safety of AngongNiuhuang Pill for the Treatment of Patients With Acute Ischemic Stroke.

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

Also called NCT03733002

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT03733002
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT03733002. Randomized; double masking; primary purpose treatment. Start 2018-12-01 (anticipated); primary completion 2019-12-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of AngongNiuhuang Pill for the Treatment of Patients With Acute Ischemic Stroke.
Acronym
AGNH2018
Condition
Acute Ischemic Stroke
Intervention (Drug)
AngongNiuhuang pill
Intervention (Drug)
Placebo of AngongNiuhuang pill
Intervention (Other)
Standard treatment
Lead sponsor
Peking Union Medical College Hospital (class: other)
Collaborator
China-Japan Friendship Hospital (class: other)
Collaborator
Cangzhou Central Hospital (class: other)
Collaborator
The Second Hospital of Hebei Medical University (class: other)
Collaborator
Affiliated Hospital of Chengde Medical University (class: other)

Record details

Record id
cardio:ct-nct03733002
Content hash
7177ac31756eaf487dc97e6db60fe71d05b2ce3c3ef4cbe45f9d5b0cd01a635f